Background Cancer immunotherapy represents a rapidly advancing frontier in oncology. Its increasing integration with established treatment modalities underscores the necessity for healthcare providers (HCPs) to be well-informed. Awareness among HCPs is critical for effective multidisciplinary collaboration and optimal patient care. This study aimed to assess HCPs' awareness and perceptions of cancer immunotherapy. Methods A cross-sectional study was conducted using a self-administered questionnaire among HCPs in the Qassim region of Saudi Arabia between November 2022 and March 2023. The survey evaluated perceptions and self-reported knowledge regarding cancer immunotherapy and its associated side effects. Results Among 374 participants (mean age: 41 years; 62% male, 38% female), 35% had ≥10 years of professional experience. Overall knowledge was low, with 258 participants (69%) scoring poorly. A majority (201, 53.7%) considered chemotherapy the best treatment option, while 159 (42.5%) perceived immunotherapies as the most expensive modality. A significant knowledge gap was evident, with 269 HCPs (71.9%) reporting a lack of familiarity with immunotherapy and 163 (43.6%) expressing uncertainty about its effectiveness compared to other therapies. The need to address this knowledge deficit was affirmed by 304 respondents (81.3%). Conclusion This study reveals poor perceived knowledge of cancer immunotherapy among HCPs in the region, a prevalent preference for chemotherapy as the optimal treatment, and a common perception of immunotherapy as costly. To bridge this gap, we recommend promoting HCP engagement in specialized field workshops and updating educational curricula, as better knowledge will increase appropriate use and improve outcomes, which strengthens policy support and public trust.
Ismail et al. (Sun,) studied this question.